Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesExopharm Ltd

Exopharm Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2024-07-02T06:45:02.273683Z
Market Cap
27.34M

Momentum Score

…

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
1.18M
Revenue Per Share
0.01
Gross Profit TTM
0.03M
Debt / Equity
0.37
ROE
-121.54%
Net Debt
-0.11M
ROCE
-163.18%
Diluted EPS TTM
-0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.13M -10.08M -8.47M -5.28M -2.28M
Net income -7.13M -10.17M -8.46M -5.22M -2.19M
Selling general administrative 6.41M 9.39M 7.90M 4.65M 1.36M
Selling and marketing expenses 0.09M 0.29M 0.33M 0.14M -
Gross profit 0.62M 0.10M - 2.62M -0.50M
Reconciled depreciation 1.70M 1.73M 1.01M 0.38M 0.06M
Ebit -6.80M -10.00M -12.67M -8.00M -2.37M
Ebitda -5.10M -8.27M -11.66M -7.62M -2.31M
Depreciation and amortization 1.70M 1.73M 1.01M 0.38M 0.06M
Operating income -6.80M -10.00M -12.67M -8.00M -2.37M
Other operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Interest expense 0.33M 0.08M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.02M 0.00M 0.01M 0.06M 0.03M
Net interest income -0.31M -0.08M 0.01M 0.06M 0.03M
Income tax expense 3.11M 0.08M -0.01M -0.06M -0.09M
Total revenue 0.62M 0.10M 4.20M 2.62M 0.03M
Total operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Cost of revenue - - - - 0.50M
Total other income expense net 2.77M -0.08M 4.20M 2.73M 0.09M
Net income from continuing ops -7.13M -10.08M -8.47M -5.28M -2.28M
Net income applicable to common shares -7.13M -10.08M -8.47M -5.28M -2.28M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 5.88M 13.61M 21.46M 6.54M 5.40M
Intangible assets 0.28M 0.33M 0.33M 0.33M 0.33M
Other current assets 2.72M 4.17M 3.96M 2.11M 0.11M
Total liab 1.75M 4.81M 2.59M 1.53M 0.28M
Total stockholder equity 4.13M 8.81M 18.87M 5.02M 5.12M
Other current liab 0.14M 0.81M 0.89M 0.47M 0.24M
Common stock 36.73M 34.31M 34.30M 12.76M 7.58M
Capital stock 36.73M 34.31M 34.30M 12.76M 7.58M
Retained earnings -33.42M -26.29M -16.21M -7.74M -2.46M
Other liab 0.04M 0.04M 0.04M - -
Other assets - 0.58M 0.45M 0.32M -
Cash 1.64M 4.85M 12.72M 1.74M 4.42M
Cash and equivalents - - 12.72M 1.74M 4.42M
Total current liabilities 1.71M 4.46M 1.77M 0.92M 0.28M
Net debt -0.11M -1.10M -11.37M -0.83M -4.42M
Short term debt 1.53M 3.44M 0.57M 0.31M 0.00M
Short long term debt 1.53M 2.75M - - -
Short long term debt total 1.53M 3.74M 1.36M 0.91M -
Other stockholder equity 0.82M 0.78M 0.78M 0.38M 0.06M
Property plant equipment 1.01M 3.25M 3.48M 1.84M 0.49M
Total current assets 4.59M 9.46M 17.20M 4.06M 4.58M
Long term investments - - - 0.28M -
Net tangible assets 3.84M 8.48M 18.54M 4.69M 4.79M
Short term investments 0.00M 0.00M - - -
Net receivables 0.07M 0.13M 0.22M 0.09M 0.05M
Inventory 0.16M 0.31M 0.30M 0.11M -
Accounts payable 0.04M 0.21M 0.31M 0.14M 0.04M
Accumulated other comprehensive income 0.82M 0.78M 0.78M -0.38M -0.06M
Common stock total equity - - - 12.76M 7.58M
Non currrent assets other - 0.58M 0.45M 0.04M 0.82M
Non current assets total 1.30M 4.15M 4.26M 2.48M 0.82M
Capital lease obligations - 1.00M 1.36M 0.91M -
Long term debt total 0.00M 0.30M 0.78M 0.60M 0.00M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.28M -1.24M -1.80M -0.95M -0.86M
Change to liabilities -2.75M 2.67M 1.07M 0.33M 0.07M
Total cashflows from investing activities -0.28M -1.24M -1.80M -0.95M -0.86M
Net borrowings -1.87M 1.95M -0.49M -0.18M -0.18M
Total cash from financing activities 0.92M 1.88M 20.61M 4.97M 7.41M
Change to operating activities 1.04M 3.93M 1.76M -0.04M -0.03M
Net income -7.13M -10.17M -4.27M -2.55M -2.19M
Change in cash -3.20M -7.88M 10.98M -2.68M 4.37M
Begin period cash flow 4.85M 12.72M 1.74M 4.42M 0.05M
End period cash flow 1.64M 4.85M 12.72M 1.74M 4.42M
Total cash from operating activities -3.85M -8.44M -7.83M -6.70M -2.18M
Issuance of capital stock 1.57M - 22.00M 5.18M 7.41M
Depreciation 1.74M 1.73M 1.01M 0.38M 0.06M
Other cashflows from investing activities 0.01M -0.11M -0.17M -0.32M -0.32M
Sale purchase of stock 1.57M 0.00M -0.84M 5.18M 7.41M
Other cashflows from financing activities 2.56M 1.88M -0.49M -0.21M -0.86M
Change to netincome 3.24M -6.77M -3.20M -2.09M -2.09M
Capital expenditures 0.28M 1.13M 1.63M 0.63M 0.86M
Change in working capital 4.14M 3.97M 2.39M 0.62M 0.03M
Other non cash items - 8.44M 7.46M 4.90M 2.22M
Free cash flow -4.13M -9.56M -9.45M -0.63M -0.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Exopharm Ltd

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.

697 Burke Road, Camberwell, VIC, Australia, 3124

61 3 8419 0827

https://exopharm.com

Name Title Year Born
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D. Founder, Technology Co-Founder, CEO MD & Director NA
Dr. Michael L. West Ph.D. Chief Technology Officer 1964
Mr. David Oxley Pres of International NA
Dr. Gregor Lichtfuss M.Sc. Co-Founder & Bus. Services Mang. NA
Mr. Johannes Muhl Sr. VP of Fin. NA
Caitlin Gladman VP of Communications NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Dr. Gregor Lichtfuss M.Sc. Co-Founder & Business Services Manager NA
Mr. Johannes Muhl Senior Vice President of Finance NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…